Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan.
Hepatol Res. 2009 Mar;39(3):223-30. doi: 10.1111/j.1872-034X.2008.00458.x. Epub 2008 Nov 5.
We previously reported the benefits of hepatic arterial infusion chemotherapy (HAIC) using cisplatin (CDDP), 5-fluorouracil (5-FU) [low-dose FP], and leucovorin/isovorin for advanced hepatocellular carcinoma (HCC). In this study, we investigated the efficacy of combination therapy with HAIC and subcutaneous interferon (IFN)- alpha-2b in patients with advanced HCC.
Of the 48 patients, 31 received low-dose FP with leucovorin/isovorin (HAIC group) and 17 received combination therapy comprising low-dose FP with isovorin and subcutaneous IFN-alpha-2b (combination group). Prognostic factors were evaluated by univariate and multivariate analyses of the patient and the disease characteristics.
There were no significant differences in the response rate (patients with complete or partial response/all patients; P = 0.736) and survival (P = 0.399) between both groups. Univariate analysis revealed that IFN therapy was not a significant prognostic factor. Multivariate analysis showed 3 variables, namely, Child-Pugh score (P = 0.010), alpha-fetoprotein level (P = 0.0047), and additional therapy (P = 0.002), to be significant prognostic factors.
We considered that combination therapy with HAIC and subcutaneous interferon (IFN)-alpha-2b was not beneficial for advanced HCC.
我们先前报道了顺铂（CDDP）、5-氟尿嘧啶（5-FU）[低剂量 FP]和亚叶酸/甲酰四氢叶酸联合肝动脉灌注化疗（HAIC）治疗晚期肝细胞癌（HCC）的获益。在这项研究中，我们研究了 HAIC 联合皮下干扰素（IFN）-α-2b 治疗晚期 HCC 患者的疗效。
48 例患者中，31 例接受低剂量 FP+亚叶酸/甲酰四氢叶酸（HAIC 组），17 例接受低剂量 FP+亚叶酸+皮下 IFN-α-2b（联合组）治疗。通过对患者和疾病特征的单因素和多因素分析，评估预后因素。
两组间的客观缓解率（完全或部分缓解的患者/所有患者；P = 0.736）和生存情况（P = 0.399）无显著差异。单因素分析显示 IFN 治疗不是显著的预后因素。多因素分析显示 3 个变量，即 Child-Pugh 评分（P = 0.010）、甲胎蛋白水平（P = 0.0047）和辅助治疗（P = 0.002）是显著的预后因素。
我们认为 HAIC 联合皮下 IFN-α-2b 治疗晚期 HCC 无益。
